Absci Corp (ABSI)

Absci is a clinical-stage, AI-native biopharmaceutical company that develops differentiated antibody therapeutics. Its Integrated Drug Creation platform pairs Origin-1, its generative AI model for de novo antibody design, with a wet-lab "lab-in-the-loop" that validates the designs. The company focuses on underexplored biological mechanisms with high unmet medical need and little competition. It reports taking its first two programs from AI design to IND (or foreign equivalent) in about two years, at roughly $15 million per program.

The lead product candidate, ABS-201, is an extended-half-life antibody against the prolactin receptor (PRLR), intended to allow a patient-friendly dosing interval. It is being developed for androgenetic alopecia (pattern hair loss) and endometriosis. The HEADLINE Phase 1/2a trial (NCT07317544) began in December 2025. It is a randomized, double-blind, placebo-controlled study expected to enroll up to 227 healthy volunteers with and without AGA at sites in Australia. The first three single-ascending-dose cohorts have been dosed with a favorable safety profile to date, and interim proof-of-concept data are expected in the second half of 2026. A Phase 2 endometriosis trial is planned for the fourth quarter of 2026, subject to HEADLINE data and regulatory considerations. As of December 31, 2025, Absci was advancing five wholly owned internal programs plus several undisclosed programs in early discovery. Origin-1, released in January 2026, comprises AbsciGen, a generative engine, and AbsciBind, which scores and filters candidates. It is designed to create full-length monoclonal antibodies against "zero-prior" epitopes and has been validated against four targets. Other platform capabilities include AI lead optimization, multispecific antibody design, and a proprietary reverse-immunology technology for target identification.

The company's business model has three parts: advancing a limited number of internal programs, such as ABS-201, through clinical development and potential commercialization; partnering or out-licensing other internal programs from preclinical through early clinical stages; and entering drug creation and co-development partnerships with third parties. Partnership terms may include upfront and research fees, milestones and royalties. Absci cites past partners including Merck, AstraZeneca and Almirall. The target markets are AGA, which affects about 80 million people in the United States, and endometriosis, which is estimated to affect about 10% of women of reproductive age worldwide. Neither has an approved durable or disease-modifying therapy, according to the company.

Absci runs a combined wet-lab and dry-lab facility of more than 77,000 square feet. It generates training data with high-throughput surface plasmon resonance, the SoluPro and ACE bacterial synthetic-biology assays, and yeast and phage display screening, and it also uses public biological datasets. Its team spans AI, drug discovery, disease biology, protein engineering and clinical development.